Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol

Clinical Nephrology

Volumn 57, Issue 4, 2002, Pages 261-273

  Urena P ^a   Bernard Poenaru, O ^a   Cohen Solal, M ^a   de Vernejoul, M C ^a  

^a CENTRE VIGGO PETERSEN   (France)

Author keywords

Alfacalcidol; Bone specific alkaline phosphatase; Parathyroid hormone; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; STEROID; VITAMIN D DERIVATIVE;

ADULT; AGED; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE REMODELING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MALE; MORPHOMETRICS; MYELOFIBROSIS; OSSIFICATION; OSTEOLYSIS; OSTEOMALACIA; PARATHYROIDECTOMY; PROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS; UREMIA;

EID: 0036215536     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP57261     Document Type: Article

References (75)

1. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro
2. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure
3. Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form and the net released is inhibited by calcium and skeletal growth factors
4. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia
5. "Pulse oral" versus intravenous calcitriol therapy in chronic hemodialysis patients
6. 1,25-dihydroxycholecalciferol effects in chronic dialysis. A double-blind study
7. 3 on the bone in patients with renal osteodystrophy
8. 3 treatment of secondary hyperparathyroidism in uremia
9. 3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis
10. 3 in patients on chronic hemodialysis
11. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis
12. Effects of 1,25-dihydroxy-cholecalciferol, the active metabolite of vitamin D in uremic man
13. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values
14. 2D therapy increases the intact parathyroid hormone secretion set point in hemodialysis patients
15. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients. Treatment with long-term intravenous calcitriol
16. 3 or partial parathyroidectomy in normal dogs
17. Oral and parenteral calcitriol for the management of end-stage renal disease
18. Alkaline phosphatase (EC 3131) in serum is inhibited by physiological concentrations of inorganic phosphate
19. Dialysis osteomalacia is associated with high bone fluoride content
20. High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population
21. Low serum levels of alkaline phosphatase of bone origin: A good marker of adynamic bone disease in hemodialysis patients
22. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D: A role for increased sensitivity to calcium
23. Bone histomorphometry in hemodialyzed patients
24. Increased bone strontium levels in hemodialysis patients with osteomalacia
25. 3 derivatives in the treatment of renal bone diseases: Justification and optimal modalities of administration
26. Regression of parathyroid hyperplasia by calcitriol pulse therapy in patients on long-term dialysis
27. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients
28. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and looser's zones independent of calcitriol?
29. Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients
30. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells
31. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy
32. Effect of alfacalcidol on natural course of renal bone disease in mild-to-moderate renal failure
33. Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function
34. 1,25-dihydroxy-cholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone
35. New concepts in renal osteodystrophy
36. Renal osteodystrophy
37. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure
38. Serum crosslaps as marker of bone resorption in dialysis patients
39. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism
40. Alfacalcidol therapy biphasically modifies the relationship between the plasma levels of intact PTH and osteocalcin in dialysis patients
41. Pulse oral calcitriol in uremic patients: Rapid modification of parathyroid response to calcium
42. 2) cells and inversely regulate the level of alkaline phosphatase mRNA
43. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
44. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients
45. Effect on serum parathyroid hormone of intravenous treatment with alfacalcidol in patients on chronic hemodialysis
46. 3 on circulating parathyroid hormone in renal failure
47. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism
48. Relationship between histomorphometric features of bone formation and bone cell characterization in vitro in renal osteodystrophy
49. Intravenous versus oral calcitriol therapy in renal osteodystrophy: Results of a prospective pulsed and dose-comparable study
50. 2 as sole phosphate binder
51. Intravenous calcitriol: Effects in severe secondary hyperparathyroidism
52. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure
53. Bone histomorphometry: Standardization of nomenclature symbols and units
54. 3 and dialysate with 3 mEq/l calcium concentration
55. A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum
56. Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism
57. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia
58. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
59. The role of the vitamin D endocrine system in health and disease
60. Parathyroid function as a determinant of the response to calcitriol treatment in the hemodialysis patient
61. The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients
62. Evidence that three structural genes code for human alkaline phosphatase
63. Determination of vitamin D and its metabolites in plasma from normal and anephric man
64. Regulation of the parathyroid hormone gene by calcium phosphate and 1,25-dihydroxyvitamin D
65. Regulation by vitamin D metabolites of messenger RNA for pre-parathyroid hormone gene transcription in vivo in the rat
66. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients
67. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol
68. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D
69. 2 in hemodialysis patients with moderate-to-severe secondary hyperparathyroidism
70. 3 in hemodialysis patients with severe secondary hyperparathyroidism
71. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients
72. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uremic rats
73. Plasma total versus bone alkaline phosphatase as marker of bone turnover in hemodialysis patients
74. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure
75. Isolation and characterization of a cDNA encoding a human liver/bone/kidney-type alkaline phosphatase